10 recruiting, 5 active not recruiting, 5 unknown, 4 completed. 16 Phase 2, 11 Phase 1, 5 Phase 3, 1 Early Phase 1.
Follow Metastatic Gastric Adenocarcinoma: new trials by email Literature Review of Metastatic Gastric Adenocarcinoma trials Research Report on Metastatic Gastric Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Biospecimen Collection, Computed Tomography, Futibatinib - Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Phase 1 | Not yet recruiting | Northwestern University | 18 | 2027-09-09 | 2026-10-20 |
| Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma Ivonescimab, FOLFOX regimen, Irinotecan - Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma | Phase 2 | Recruiting | UNICANCER | 88 | 2025-11-20 | 2026-04-28 |
| Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases Biopsy, Biospecimen Collection, Computed Tomography - Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Gastric Adenocarcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 30 | 2025-10-29 | 2025-11-10 |
| A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Subcutaneous Tislelizumab, Intravenous Tislelizumab, Cisplatin - Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | BeOne Medicines | 351 | 2025-08-27 | 2026-10-14 |
| Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine - Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Boehringer Ingelheim | 768 | 2024-06-28 | 2026-10-14 |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 224 | 2024-06-24 | 2026-10-23 |
| Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . nal-IRI /Experimental, Ramucirumab /Experimental, Trifluridine/Tipiracil /Experimental - Metastatic Gastric Adenocarcinoma, Second Line | Phase 1 / Phase 2 | Recruiting | National Health Research Institutes, Taiwan | 45 | 2024-04-01 | 2026-04-09 |
| A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer AgenT-797, Botensilimab, Balstilimab - Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2024-02-01 | 2026-05-15 |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma Fluorouracil, Leucovorin Calcium, Oxaliplatin - Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 382 | 2023-01-31 | 2026-10-02 |
| BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors BI-1607, Trastuzumab - HER2-positive Breast Cancer, HER2-positive Gastric Cancer | Phase 1 / Phase 2 | Terminated | BioInvent International AB | 18 | 2022-07-28 | 2024-12-16 |
| Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer Camrelizumab, Apatinib Mesylate - Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 2 | Unknown | Sixth Affiliated Hospital, Sun Yat-sen University | 68 | 2022-05-01 | 2022-04-22 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma Lenvatinib, Pembrolizumab - Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2022-02-14 | 2026-07-16 |
| Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction Docetaxel, Oxaliplatin, Fluorouracil - Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 2 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 79 | 2022-01-07 | 2026-07-13 |
| Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer Paclitaxel, Quality-of-Life Assessment, Ramucirumab - Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 2 | Recruiting | Academic and Community Cancer Research United | 116 | 2021-06-16 | 2024-04-01 |
| Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer Camrelizumab, Apatinib Mesylate, S1 - Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 2 | Unknown | Zhou Fuxiang | 35 | 2021-05-14 | 2021-05-17 |
| Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer Berzosertib, Computed Tomography Assisted Biopsy, Endoscopic Biopsy - Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2020-11-16 | 2026-10-20 |
| Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body Capecitabine, Fluorouracil, Leucovorin - Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8 | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 314 | 2020-05-26 | 2026-10-19 |
| Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors Pembrolizumab, Sonidegib - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8 | Phase 1 | Active not recruiting | Mayo Clinic | 36 | 2020-02-13 | 2026-03-18 |
| Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer Paclitaxel - Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 27 | 2019-12-06 | 2026-10-06 |
Showing 20 of 27. Sign in to see all of them.
Adenocarcinoma Of Esophagus (7) · Neoplasm Metastasis (3) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Transitional Cell (2) · Lung Neoplasms (2) · Melanoma (2) · Peritoneal Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Stomach Neoplasms (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Lobular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Renal Cell (1)
Neoplasms (7) · Neoplasms by Site (7) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Carcinoma (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Head and Neck Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Neoplastic Processes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3)
Paclitaxel (9) · Ramucirumab (8) · Oxaliplatin (7) · Fluorouracil (6) · Magnetic Resonance Spectroscopy (6) · Taxes (5) · Capecitabine (4) · Irinotecan (4) · Leucovorin (4) · Specimen Handling (4) · apatinib (4) · pembrolizumab (4) · Biopsy (3) · Docetaxel (3) · S 1 (combination) (3)
China Medical University, China (2) · City of Hope Medical Center (2) · Eli Lilly and Company (2) · M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · National Cancer Institute (NCI) (2) · Sixth Affiliated Hospital, Sun Yat-sen University (2) · Academic and Community Cancer Research United (1) · Alliance for Clinical Trials in Oncology (1) · BeOne Medicines (1) · BioInvent International AB (1) · Boehringer Ingelheim (1) · ECOG-ACRIN Cancer Research Group (1) · Memorial Sloan Kettering Cancer Center (1) · Millennium Pharmaceuticals, Inc. (1)
United States (16) · China (8) · Japan (5) · France (4) · South Korea (4) · Spain (4) · United Kingdom (4) · Germany (3) · Italy (3) · Puerto Rico (3) · Taiwan (3) · Argentina (2) · Belgium (2) · Czechia (2) · Mexico (2)
Andres McAllister, MD, PhD (1) · Anwaar Saeed (1) · Brian D Badgwell (1) · Gladys Rodriguez, MD (1) · Hongming Pan, MD (1) · Jian Xiao, MD (1) · Jian Xiao, PhD (1) · Jordan D Berlin (1) · Joseph Chao (1) · Mariela Blum (1) · Mohamad B Sonbol (1)
PMID 11230497, PMID 11489791, PMID 11895891, PMID 16271446, PMID 1651156, PMID 17468871, PMID 18172173, PMID 18971936, PMID 19349540, PMID 21296855, PMID 21742485, PMID 22811849, PMID 23406728, PMID 23880820, PMID 23918952, PMID 25577133, PMID 26615328, PMID 27091418, PMID 27871319, PMID 30718072, PMID 31373648, PMID 34795131, PMID 35602670, PMID 40155326, PMID 40468090, PMID 41071338, PMID 41108088, PMID 41335461, PMID 42669571
2025 (2), 2014 (1), P30CA015083 (1), P30CA033572 (1), P30CA060553 (1), U10CA180820 (1), U10CA180888 (1), UM1CA186689 (1)